Relapsed Hematologic Malignancy Clinical Trials

11 clinical trials for Relapsed Hematologic Malignancy across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products — RECRUITING
• CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) — RECRUITING · PHASE1
• International Leukemia Target Board — RECRUITING
• PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma — RECRUITING · NA
• A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor — RECRUITING · PHASE1
• Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant — COMPLETED · PHASE2
• A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. — WITHDRAWN · PHASE1
• Impact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist on the Care Pathway for Cancer Patients Treated With Oral Therapy — OTHER · NA
• Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant — OTHER · PHASE1
• Extended Analysis for Leukemia/Lymphoma Treatment — COMPLETED

Refine this search